American Society of Hirudotherapy

Destabilase-3

Paralog variant of destabilase identified in Hirudo medicinalis sialotranscriptome — isopeptidase/lysozyme bifunctional family member.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Last Updated: May 26, 2026 · ASH Editorial · based on the books
  • Hementerin80 kDa
  • Hementin80 kDa
  • Hementin-Like Protein (HLP-1)80 kDa
  • Leech Collagenase70 kDa
  • Haemadipsa yanyuanensis Progranulin (Hy-PGRN)70 kDa
  • Leech Apyrase67 kDa
  • Calin65 kDa
  • Hyaluronidase60 kDa
  • Antithrombin III binding protein58 kDa
  • Collagenolytic Fibrinolysin55 kDa
  • Leech Thrombospondin-Like Protein50 kDa
  • Destabilase-312.5 kDa
Molecular weight (kilodaltons) of Destabilase-3 (highlighted) alongside other characterized leech salivary compounds. Smaller proteins/peptides generally diffuse and act faster.

Mechanistic Evidence Box

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.
Page type
Compound profile
Evidence type
Preclinical / biochemical characterization
Evidence level
In vitro
Drug vs leech
Purified natural compound
Safety domains
Bleeding

Clinical translation limit

Destabilase-3's predicted bifunctional activity (isopeptidase + lysozyme) does NOT establish clinical efficacy as a thrombolytic or antimicrobial agent. No FDA-approved derivative exists.

Molecular Profile

Category
Fibrinolytic
Evidence tier
Preclinical
Molecular weight
12,500 Da
Source species
Hirudo medicinalis
Discovered
2018

Biological Targets

  • → ε-(γ-Glu)-Lys isopeptide bonds in cross-linked fibrin
  • → bacterial peptidoglycan

Key Citations

  1. Fadeeva IuI et al. (2014), Biomed Khim · PMID 25019395

External Resources

    Related Fibrinolytic Compounds

    This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.